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Abstract Evidence suggests that multiple tumors,
including pancreatic adenocarcinoma, display heterogene-
ity in parameters that are critical for tumor formation,
progression and metastasis. Understanding heterogeneity in
solid tumors is increasingly providing a plethora of new
diagnostic and therapeutic approaches. In this study, a
particular focus was put on identifying a subpopulation of
stem cell-like, slow cycling tumor cells in a pancreas
adenocarcinoma cell lines. Using a label retention tech-
nique a subpopulation of slow cycling cells (DiI?/SCC)
was identiﬁed and further evaluated in the BxPC-3 and
Panc03.27 cell lines. These slowly cycling cells managed
to retain the lipophilic labeling dye DiI, while the bulk of
the cells ([94%) did not. The DiI?/SCC population,
showed only a partial overlap with the CSC markers
CD24
?/CD44
?, CD133
? and ALDH but they survived
chemotherapeutic treatment, and were able to recreate the
initial heterogeneous tumor cell population. DiI?/SCCs
exhibited an increased invasive potential as compared with
their non-label retaining, faster cycling cells (DiI-/FCC).
They also had increased tumorigenic potential and mor-
phological changes resembling cells that have undergone
an epithelial to mesenchymal transition (EMT). Analysis of
DiI?/SCC cells by real time PCR revealed a selective up-
regulation of tell tale components of the Hedgehog/TGFb
pathways, as well as a down-regulation of EGFR, com-
bined with a shift in crucial components implied in EMT.
The presented ﬁndings offer an expanded mechanistic
understanding that associates tumor initiating potential
with cycling speed and EMT in pancreatic cancer cell lines.
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Abbreviations
5-FU 5-Fluorouracil
EMT Epithelial to mesenchymal transition
MET Mesenchymal to epithelial transition
CSC Cancer stem cell
Shh Sonic hedgehog
Hh Hedgehog
Gli1 Glioma-associated oncogene homolog 1
PTCH Patched protein homolog 1
TGFb Transforming growth factor beta
EGFR Epidermal growth factor receptor
MMP-2 Matrix metalloproteinase-2
MMP-9 Matrix metalloproteinase-9
ALDH Aldehyde dehydrogenase
DiI?/SCC DiI positive (label retaining), slow cycling
cell
DiI-/FCC DiI negative (label lost), fast cycling cell
Introduction
Pancreatic cancer is known for its extensive local tumor
invasion and early systemic dissemination. The molecular
basis for these characteristics is not yet fully understood.
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DOI 10.1007/s10585-009-9260-0Therefore, despite advances in surgical and medical ther-
apy, little effect has been made on the mortality rate of this
disease [1].
Most attempts to better understand the characteristics of
pancreatic adenocarcinoma have focused on studying gene
andproteinexpressionproﬁlesoftotalsamplesofpancreatic
adenocarcinoma, and have not taken into account the het-
erogeneity of cells within a particular tumor. However,
based on the concept of cancer stem cells (CSC), claims are
made that the ability of a tumor to grow and propagate may
dependonsmallsubsetsofcells,asonlyaminorityofcancer
cells showed extensive proliferation when examined for
their proliferative potential in various in vitro or in vivo
assays [2–4]. In particular cells that are either positive for
the surface antigens CD24 and CD44, CD133 or display
ALDH activity have been reported to exhibit increased self
renewal and tumor initiating potential, as well as to give rise
to renewed heterogeneity in pancreas adenocarcinoma [3–
7]. Cells with such properties are termed by various authors
‘‘CSC’’ or ‘‘tumor initiating cells’’.
Interestingly, the CD24
?/CD44
? cells in pancreas ade-
nocarcinoma also display increased expression of compo-
nents of the sonic hedgehog (Shh) stem cell signaling
pathway [3, 7]. However, the role of the Hh signaling path-
wayanditsmediator,thezincﬁngertranscriptionfactorGli1
[8],inetiologyandprogressionofpancreasadenocarcinoma
isnotfullyunderstood, although there isevidence tosupport
a role of the Hh pathway in this tumor. The central impor-
tance of Gli1 mediated signaling was conﬁrmed by a broad
genetic analysis of pancreatic cancer that identiﬁed genetic
alterations in 100% of samples, together with changes in
KRAS,TGF,andWnt/Notch.[9].All4pathwaysarecentral
in developmental and stem cell biology where they control
cell cycle, developmental potential, cell adhesiveness and
apoptosis [8, 10]. Although the involvement of these path-
ways in tumors is well established, less is known about their
role and involvement in tumor heterogeneity or subpopula-
tions. Analysis of the correlation of pathways to subpopu-
lations will be of substantial signiﬁcance.
It is believed that subpopulations of cells within the
tumor microenvironment can undergo changes and are the
main contributor to metastatic disease. Interestingly, a
recent study where a chemo-resistant population of pan-
creatic cancer cells was created, suggested that the resistant
population of cells had undergone EMT changes and was
now of a more motile invasive phenotype as compared to
the parental line [11]. EMT, as controlled by develop-
mental pathways, is a key player in cancer metastasis as it
allows cells to migrate and invade surrounding issues and
escape into the bloodstream, en route to establishing
metastasis. Once these metastatic cells reach their desti-
nation, they can undergo reverse EMT—mesenchymal
epithelial transition (MET), to establish secondary tumors.
Consequently, EMT stimuli can generate cells with
properties of stem or progenitor cells. In a recent report,
normal mammary epithelial cells were induced to acquire
the CD44
high/CD24
low breast CSC phenotype after expo-
sure to TGFb [12]. This implies that expression of TGFb
either converts CD44
low/CD24
high cells to the CD44
high/
CD24
low CSC phenotype, thereby suggesting that the
majority of cells have the possibility to switch to this CSC
phenotype; or that the EMT stimuli inhibits the prolifera-
tion of the epithelial tumor cell population and induces the
proliferation or stops the differentiation of the CSC. As a
result, it has been suggested that CSCs may actually not be
distinct entities, but rather tumor cells that transiently
acquire stem cell-like properties as a consequence of EMT
[13]. Such transient subpopulations of cancer cells with
stem cell character may not only have an increased innate
ability to resist chemo and radio therapies [14–16], but may
carry a speciﬁc proﬁle of developmental signals, which
could make them amenable to therapeutic approaches
through speciﬁc pathway antagonists.
In this report, a subpopulation of DiI?/SCC in the
pancreatic adenocarcinoma cell lines BxPC-3 and
Panc03.27 was identiﬁed, selected upon and sorted by cell
cycle speed. The resulting population (DiI?/SCC) was
overlapping, but not identical, with the previously reported
pancreatic population of tumor initiating cells (CD133
?,
ALDH?, or CD24
?/CD44
?). DiI?/SCCs were morpho-
logically distinct and showed a more malignant, invasive
and neoplastic phenotype when compared to the fast
cycling bulk of cells (DiI-/FCC). Quantitative RT-PCR
proﬁling conﬁrmed that DiI?/SCC showed alterations in
key developmental and stem cell signaling pathways, and
an expression proﬁle consistent with EMT conversion.
Materials and methods
Cells and culture conditions
BxPC-3 and Panc03.27 pancreatic adenocarcinoma cells
were obtained from ATCC and were cultured in RPMI
media (Sigma–Aldrich) containing 10% FBS (Invitrogen)
with 2 mmol/l glutamine and penicillin/streptomycin
(BioWhittaker) either 10 ll ITS (BxPC-3) or 500 ll ITS
(Panc03.27) (Sigma–Aldrich) at 37C in a humidiﬁed
atmosphere of 5% CO2.
Labeling and sorting of cell populations
Vybrant
 DiI cell-labeling solution (Invitrogen/Molecular
Probes), was used to label cells, according to the protocol
for attached cells [17]. The labeled cells were then allowed
to grow for 4–6 weeks (passaging when conﬂuent, and
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123retaining all cells through the period), and were analyzed
and sorted using a BD FACS Aria (VWR). As positive
controls, freshly labeled cells were used, whereas the
negative control consisted of cells that never came in
contact with the dye. When sorting, the brightest positive
population was selected and used in further analysis. Data
represent means ± SD; n = 20 (BxPC-3); n = 9
(Panc03.27).
Flow cytometry
Previously DiI labeled cells were trypsinized (Trypsin-
EDTA, Biowhittaker), resuspended in PBS and sorted on
BD FACS Aria using BD FACS Diva software.
To analyze expression of CSC markers, freshly sorted
cell populations were immediately stained with mouse anti-
human CD44-PE/Cy7 and CD24-PE or CD24-FITC (both
from Abcam) as such; cells were washed and re-suspended
in PBS with 10%FBS, then incubated with 10 ll of each
antibody in 100 ll for 1 h (in the dark, on ice). Cells were
then washed 3 times, resuspended in PBS with 10% FBS,
and immediately re-analyzed by FACS.
To analyze CD133 expression, 4–6 weeks DiI labeled,
unsorted cells were incubated with rabbit anti-CD133
(Abcam) (1/200 dilution in PBS 10%FBS) for 30 min (in
the dark, on ice), then washed 3 times in PBS with
10%FBS. For secondary antibody, goat anti-rabbit Alexa
488 (Invitrogen) was used (1/200 dilution in PBS 10%FBS)
for 30 min (in the dark, on ice), then washed 3 times in
PBS with 10%FBS and analyzed.
To examine ALDH expression 4–6 weeks DiI labeled,
unsorted cells were stained using the Aldeﬂuor kit (Stem-
Cell Technologies) according to manufacturer’s instruc-
tions. Data represent means ± SD;n = 3 per assay.
Chemotherapy resistance assay
Cells were labeled with DiI and seeded into six well plates
at 300,000 cells/well (BD Falcon, VWR) 24 h prior, then
treated with a 5-Fluorouracil (5-FU) (Sigma) at 0, 5, 50,
100, 150, 200 lg/ml. After 3 days, media was replaced,
and cells were followed for growth. Additionally FACS
sorted DiI?/SCC were plated, allowed to adhere overnight,
then challenged with 5-FU in a similar fashion as above.
Images were obtained on an Axiovert 200 M micro-
scope (Zeiss) using Axiovision software. Electronic images
were further processed using Adobe Photoshop.
Data represent means ± SD; n = 3 per assay.
Soft agar assay
The colony formation capability of the DiI?/SCC and
DiI-/FCC populations in soft agar was investigated.
Brieﬂy, 5000 freshly sorted cells were resuspended in
1.5 ml growth media containing 0.35% agar (Oxoid), and
plated in triplicate over a 1.5 ml base layer containing
0.5% agar in six-well plates. The plates were incubated for
14 (Panc03.27) or 21 (BxPC-3) days, then stained for 1 h
with 1 ml of 0.02% crystal violet (Sigma), and colonies
were counted. Colony diameters larger than 75 lmo r
colony cells more than 50 cells were counted as 1 positive
colony. Images were obtained on an Axiovert 200 M
microscope (Zeiss) using Axiovision software. Electronic
images were further processed using Adobe Photoshop.
Data represent means ± SD; n = 3.
Invasion assay
BD BioCoat matrigel invasion chamber 24-well plates;
8.0 lm pore size (VWR) were used in the experiment as
such; 25,000 cells were plated in the top chamber in 500 ll
of media containing 1% FBS. The bottom wells contained
750 ll of complete media (10% FBS). The cells were
allowed to grow and invade for 20 or 44 h, then the non-
invading cells were scraped from the upper surface of the
membrane with a cotton swab, and the cells on the lower
side were stained with 0.02% crystal violet in formalde-
hyde (Sigma). The number of invading cells were counted
through the entire surface area (about 9 microscopic ﬁelds
at 109). Data represent means ± SD; n = 3 for each data
point.
Animals
About 4–6 weeks old female CB17/SCID mice were used
throughout this study. All mice were housed and used
under the approved protocols in accordance with the
National Institute of Health guide for the care and use of
laboratory animals, and all efforts were made to minimize
the number and suffering of animals.
In vivo tumor establishment
Anesthesia was induced brieﬂy using open drop exposure
to isoﬂurane (Baxter) [18], then the lower ﬂank was shaved
and freshly sorted (DiI?/SCC vs. DiI-/FCC) were care-
fully injected sub cue in GFR matrigel (BD Biosciences) in
a total volume of 200 ll (1:1 matrigel:PBS) in the fol-
lowing amounts; DiI-/FCC: 1 9 10
6 (n = 3); 5 9 10
5
(n = 3), 1 9 10
5 (n = 4), 5 9 10
4 (n = 4), 1 9 10
4
(n = 4), 5 9 10
3 (n = 4) DiI ?/SCC: 1 9 10
6 (n = 3),
5 9 10
5 (n = 3), 1 9 10
5 (n = 4), 5 9 10
4 (n = 4),
1 9 10
4 (n = 4), 5 9 10
3 (n = 4). Mice were followed
over a 4 weeks period and tumor size (if present) was
measured using calipers (mm
2).
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Total RNA was isolated using the GeneElute miniprep kit
(Sigma) following the manufacturer’s instructions. cDNA
was synthesized using the Retroscript kit (Ambion), and
real-time PCR was carried out using the SYBR Green PCR
master mix (Stratagene) according to the manufacturer’s
instructions with an Mx3000P cycler (Stratagene). The
general ampliﬁcation protocol (50 cycles) was set as fol-
lows: initial denaturation for 5 min at 95C, then dena-
turation for 1 min at 95C, speciﬁc primer annealing
temperature for 30 sec (Supplementary Table 2), and
ampliﬁcation at 72C for 1 min. The concentrations of
cDNA present in each sample were calculated by the
MxPro software (Stratagene). To normalize the amount of
cDNA in each sample and to guarantee the comparability
of the calculated mRNA expression in all samples ana-
lyzed, the housekeeping gene GAPDH was also analyzed.
Primers and speciﬁc annealing temperatures are listed in
Supplementary Table S2. Data represent means ± SD;
n C 4.
Results
Isolation of slow cycling cells
To isolate slower cycling cells, a label retention method
was used with the pancreas adenocarcinoma cell lines
Panc03.27 and BxPC-3. Cells were labeled with the long
term lipophilic tracer dye, DiI (C59H97ClN2O4), which is
structurally identical to PKH26, a dye which has numerous
references regarding its use to trace cell divisions and
identify slow cycling populations such as long-term cul-
ture-initiating cells (LTC-IC) [19–23]. Advantages of DiI
to PKH26 include simple uniform cellular labeling (no
requirement for special osmolarity agents or salt in the
staining buffer), low cytotoxicity (DiI does not affect cell
viability, development, or other basic physiological prop-
erties) and high resistance to intercellular transfer. DiI, like
PKH26 has also been used to trace cells throughout divi-
sions in vitro, and has been detected throughout cell pas-
sages for as long as 7 weeks in bone marrow stromal cells
[24]. The strong, photostable ﬂuorescence and excellent
cellular retention of DiI make it highly favorable for a
number of applications, including long-term labeling and
tracking of cells [17].
As seen in Fig. 1, cells exhibited clear heterogeneity
with respect to cell cycle length, and after 6 weeks of
growth (BxPC-3; only 4 weeks were required to identify a
DiI?/SCC population with Panc03.27), a segregated,
bright DiI? retaining population of cells (DiI?/SCC)
correlating to *3% (mean = 2.9% ± 1.7 BxPC-3;
2.4% ± 1.8 Panc03.27) of the total population was visible,
traceable, and easy to sort by FACS (Fig. 1). Nearly all
DiI?/SCCs showed striking morphological changes when
compared to DiI-/FCCs. The cells exhibited an elongated
ﬁbroblast like cell shape, regardless whether they were in a
cellular context, or growing isolated. In contrast non label
retaining cells (DiI-/FCC) displayed a more compact and
epithelial morphology (Fig. 2a).
Chemotherapy resistance selects for repopulating
DiI?slow cycling cells
Slow cycling cells would be predicted to show increased
resistance to standard chemotherapy. However, resistance
to chemotherapy may also be due to other mechanisms,
including highly active drug pumps [15]. To test possible
therapeutic relevance we asked whether chemotherapy
applied to pancreas adenocarcinoma cells would selec-
tively or preferably target the DiI?/SCC or DiI-/FCC
subpopulations. After labelling, BxPC-3 and Panc03.27
cells were exposed to various doses of the base analogue
5-FU (5- Fluorouracil). 5-FU or gemcitabine is commonly
used as therapy in pancreas adenocarcinoma [25]. As seen
in Fig. 2, after a 3 day regime of 100 lg/ml 5-FU, only a
few BxPC-3 (3.5% ± 1.0; Fig. 2b) or Panc03.27 (3.3% ±
1.1; Fig. 2c) cells survived.
Next, to determine whether the DiI?/SCCs that sur-
vived 5-FU treatment could recreate the pre-selection
tumor cell culture, selective pressure was released by
reverting cells into standard growth medium. As seen in
Fig. 2, single cells started to divide by 14 days
(Panc03.27; Fig. 2c) or 20 days (BxPC-3; Fig. 2b), and
after 22 or 36 days, respectively, heterogeneous colonies
of slow and fast dividing cells had emerged from each of
the cells. Similarly, when sorted according to cell cycle
speed, and re-plated, DiI?/SCC were also able to
regenerate a pre-sorting population (Fig. 2d; data not
shown). These colonies were heterogeneous in regards to
cell cycle, as displayed by the varying intensities of DiI,
indicating that slow cycling cells can be founder cells for
fast cycling cells. Accordingly, colonies emerging from
the FACS sorted (DiI?/SCC) or 5-FU treatment survivors
showed the same pattern of fast and slow cycling cells as
the cell cultures before, strongly indicating that the che-
motherapy resistant, slow cycling cells have tumor initi-
ating and repopulating potential. These ﬁndings are
consistent with previously published data in which the
selection of a chemoresistant subpopulation of cells fol-
lowing gemcitabine treatment had increased tumor initi-
ating potential [11].
Interestingly, not only were DiI?/SCC able to give rise
to DiI-/FCC, but also the reverse mechanism was pres-
ent. Thus, when DiI-/FCCs were replated after FACS
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protocol, a distinct population of DiI?/SCC reemerged
(data not shown). In conclusion, the pancreatic
adenocarcinoma cell lines Panc03.27 and BxPC-3 contain
distinct fast and slow cycling cell populations that can
revert into each other.
Fig. 1 Cell labeling,
preparation and sorting a
Schematic illustration of
labeling, expansion and sorting
of cells. b FACS analysis of
BxPC-3 and Panc03.27 cells
after 6 and 4 weeks growth,
with 3.2 and 2.8% positive cells
(DiI?/SCC), respectively
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and invasive potential
Isolated DiI?/SCC could re-establish colonies of tumor
tissue that were visually indistinguishable from the pre-
selection cell population. To test whether such a repopu-
lating capability may go along with increased tumorige-
nicity, the capability to form colonies in soft agar between
DiI?/SCC and DiI-/FCC was compared. The sorted cell
populations were seeded in soft agar and followed over 14
(Panc03.27) or 21 (BxPC-3) days growth. By 8 days it was
already visible that DiI?/SCC colonies were more
numerous than the DiI-/FCC counterparts (data not
shown). At the conclusion of the assay, the rate of colony
formation had increased by ten fold in the BxPC-3 DiI?/
SCC population (DiI?/SCC 13.4 ± 1.1; DiI-/FCC
1.3 ± 1.0) and 2.5-fold in the Panc03.27 DiI?/SCC pop-
ulation (DiI?/SCC 11.4 ± 1.0; DiI-/FCC 4.6 ± 1.0), as
compared to their corresponding DiI-/FCC population
(Fig. 3a).
Next, the invasive potential of DiI-/FCC and DiI?/
SCC populations was compared. Using BD matrigel coated
invasion plates, freshly sorted DiI?/SCC and DiI-/FCC
were allowed to grow and invade for 20 or 44 hours.
Already after 20 h, the BxPC-3 DiI?/SCC population had
a 2.5-fold increase in invading cells versus the DiI-/FCC
population (DiI?/SCC 66 ± 14.1; DiI-/FCC 26 ± 4.2),
while the Panc03.27 DiI?/SCC population had a two fold
increase (DiI?/SCC 213 ± 22.6; DiI-/FCC 107 ± 22.3)
(Fig. 3b). At 40 h, the invasive potential of BxPC-3 DiI?/
SCC increased to four fold over the DiI-/FCC population
(DiI?/SCC 445 ± 52.4; DiI-/FCC 109 ± 13.4) and 4.5-
fold in Panc03.27 DiI?/SCC (DiI?/SCC 602.5 ± 13.4;
DiI-/FCC 131.5 ± 17.7). In summary, these results sug-
gest that the DiI?/SCC population consists of highly
tumorigenic cells with increased invasive and metastatic
potential compared to the DiI-/FCC population.
Slow cycling cells have increased tumor formation
ability
Several reports show a strongly increased potential of
selected populations in pancreas adenocarcinoma and other
solid tumors to initiate tumor growth in SCID mice [3, 26–
28]. To examine tumorigenicity freshly sorted DiI?/SCC
and DiI-/FCC populations from BxPC-3 were injected to
CB17/SCID mice. BxPC-3 cells are described in the lit-
erature to require 10
7 cells for tumor formation in nude
mice [29]. In our hands, 5 9 10
6 BxPC-3 cells were
capable of forming tumors in CB17/SCID mice, and in a
Fig. 2 Cell growth after DiI labeling. a Image of DiI?/SCC and
DiI-/FCC cells after 4 (Panc03.27) or 6 (BxPC-3) weeks growth;
before and after (BxPC-3) sorting (plated for high resolution imagery
and taken after 24 h). b BxPC-3 normal growth (top) or with the
addition of 100 lg/ml 5-FU (treated with 5-FU for 3 days) (bottom)
of cells followed through 36 days. c Panc03.27 normal growth (top)
or with the addition of 100 lg/ml 5-FU (treated with 5-FU for 3 days)
(bottom) of cells followed through 22 days. d Growth of plated DiI?/
SCC after sorting (times represent growth duration after plating).
Scale bars represent 100 lm
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in vivo, similar tumorigenicity was observed when tumors
were initiated by injecting cells to as little as 2 9 10
6.I t
was only at injections of cell numbers below this level that
suggested an increased tumorigenicity of the DiI?/SCC
population (data not shown). Therefore, we further
examined the tumor initiating potential of DiI?/SCC vs.
DiI-/FCC at 1 9 10
6 and below in this study. As seen on
Table 1, injection of DiI?/SCCs resulted in an enhanced
tumorigenic potential when compared to the DiI-/FCC
population. After injection of 10
4 cells, 75% (3/4) of mice
receiving DiI?/SCC had established tumors, while no
Fig. 3 Invasion and Colony
Forming Assays a Soft agar
assay for colony formation.
Graph represents results after 14
(Panc03.27) or 21 (BxPC-3)
days of culture with DiI?/SCC
or DiI-/FCC sorted
populations. An increase in
colony formation was seen with
the DiI?/SCC population. b
Invasion assay run with freshly
sorted DiI?/SCC vs. DiI-/FCC
populations. Results show
increased invasive potential of
the DiI?/SCC population over
the DiI-/FCC population after
20 and 44 hours
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tumors formed after injection of as few as 5 9 10
3 DiI?/
SCCs (1/4), while no tumor established from DiI-/FCCs
until at least 5 9 10
4 cells were injected. This represents a
ten fold increase in tumorigenic potential and supports our
previous in vitro results.
Slow cycling cells display increased expression
of cancer stem cell markers
Previously published data report the existence of a phe-
notypically distinct and relatively rare population (0.5–2%)
of CD24
?/CD44
? CSC in primary pancreatic adenocarci-
noma that have an enhanced ability to form tumors when
compared with the bulk population of tumor cells or
CD24
-/CD44
- populations [3]. As seen in Fig. 4a, 6.2%
(mean = 6.0% ± 0.9) of the total BxPC-3 cell population
and 10.4% (mean = 11.3% ± 2.4) of the total Panc03.27
cell population was double positive for CD24
?/CD44
?.
Interestingly, when the sorted DiI?/SCC fraction was
analyzed, the number of CD24
?/CD44
? cells increased
almost ten fold in BxPC-3 to 56.7% (mean = 56.2%
± 8.9) and greater than two fold in Panc03.27 to 25.5%
(mean = 24.5 ± 1.4), demonstrating an overlap between
the already described CD24
?/CD44
? population, and the
here presented DiI?/SCC population. Interestingly,
although all cells are CD44
?, only a fraction of the DiI?/
SCC are CD24
?, while others remain CD24
-.
Next, we examined the expression of CD133, another
CSC marker that has been reported in pancreatic carcino-
mas, to determine if any correlation with DiI?/SCC exists
[5]. As seen in Fig. 4b, 3.9% (mean = 3.7% ± 1.2) of the
total BxPC-3 cell population and 0.6% (mean = 0.7%
± 0.1) of the total Panc03.27 cell population was positive
for CD133. When examining the DiI?/SCC fraction in
detail, 7.1% (mean = 7.0% ± 0.2) of BxPC-3 and 3.8%
(mean = 4.7% ± 1.3) of Panc03.27 DiI?/SCCs expressed
CD133. This indicates an overlap between the known
CD133
? CSC population and the here presented DiI?/SCC
population again.
Finally, we looked at aldehyde dehydrogenase (ALDH)
activity, a marker which has been used to identify both
normal and malignant stem cells [6, 7]. Using the aldeﬂuor
assay, we were able to investigate if there was a correlation
between ALDH positive cells and DiI?/SCC. As shown in
Fig. 4c, just 1.3% (mean = 2.1% ± 1.5) of total BxPC-3
cells were ALDH
?, while 24.2% (mean = 25.5% ± 1.8)
of all Panc03.27 cells were ALDH
?. This correlates to
5.4% (mean = 5.3% ± 0.1) of the BxPC-3 DiI?/SCC
population and 63.0% (mean = 59.6% ± 4.8) of the
Panc03.27 DiI?/SCC being ALDH
?. These results there-
fore suggest that although overlap between the previously
identiﬁed CSC markers exists, slowly cycling DiI? cells
are a distinct and unique population of cancer stem-like
cells.
DiI?/SCCs express markers associated with EMT,
stem cell regulation and metastatic potential
To further determine molecular characteristics of the
DiI?/SCC and DiI-/FCC subpopulations, quantitative
RT-PCR proﬁling was performed. Since factors speciﬁ-
cally associated with the conversion of early stage tumors
into invasive malignancies through an EMT were partic-
ularly of interest, the gene expression proﬁle of Snail,
Twist, E-Cadherin, N-Cadherin, and Vimentin was ana-
lyzed. As seen in Fig. 5a, DiI?/SCC showed decreases in
snail and E-cadherin, while the expression level of N-
cadherin was increased when compared to the DiI-/FCC
population. Additionally, twist and vimentin were strongly
increased in BxPC-3 DiI?/SCC. These alterations are
characteristic for cells undergoing EMT [30, 31], and
support the observed morphological change along with the
increased invasiveness and metastatic potential of the
DiI?/SCC population.
Next indicative markers for increased metastatic
potential (MMP-2, MMP-9), and apoptosis protection (Bcl-
xl, BCL-2) were analyzed. Both features are prominent in
aggressive tumor progression and therapeutic resistance.
Thus, upregulation of MMP-2, Bcl-xl and Bcl-2 imply
metastatic potential in these cells. Basement membrane
degradation through MMPs and subsequent protection
from apoptosis (Bcl-xl, Bcl-2) after detachment from the
basement membrane occur throughout stages of metastasis
[32]. Real time PCR on the DiI?/SCC population revealed
a clear increase of MMP-2, but a moderate decrease of
MMP-9. Furthermore, expression levels of Bcl-xl and Bcl-
2 were moderately increased (Fig. 5a).
Stem cell pathways have shown to play a crucial role in
pancreas adenocarcinoma, and components of the
Table 1 Tumor formation ability of freshly sorted DiI?/SCC versus DiI-/FCC subpopulations injected subcutaneously into SCID mice
Cell population/Cell number 1 9 10
6 5 9 10
5 1 9 10
5 5 9 10
4 1 9 10
4 5 9 10
3
DiI-/FCC 3/3 3/3 2/4 2/4 0/4 0/4
DiI?/SCC 3/3 3/3 4/4 3/4 3/4 1/4
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123Fig. 4 Expression of CSC
markers a FACS analysis of
percent CD24
?/CD44
? cells in
the bulk verses DiI?/SCC
populations. b FACS analysis of
percent CD133
? cells in the
bulk and DiI?/SCC
populations. c FACS analysis of
percent ALDH
? cells in the
bulk and DiI?/SCC populations
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123Hedgehog, Wnt/Notch, KRAS and TGFb pathways are
found to be de-regulated in 100% of analyzed pancreas
adenocarcinoma samples [9]. We therefore asked whether
members of these central pathways are differentially
expressed in fast cycling, and slow cycling pancreas ade-
nocarcinoma cells. Indeed, when compared to the DiI-/
FCC population, Shh was increased nearly four fold in
BxPC-3 and two fold in Panc03.27 and the zinc ﬁnger
transcription factor Gli1, was up-regulated 2.5-fold in
BxPC-3 and 1.5-fold in the Panc03.27 DiI?/SCC popula-
tions. In contrast, PTCH1, the receptor for Shh and a
negative regulator of the pathway was found to be slightly
down regulated in BxPC-3 DiI?/SCC and slightly
increased in the Panc03.27 DiI?/SCC population. Finally,
TGFb, which regulates a diverse array of cellular functions
is a key participant in many tumor microenvironments [33],
and has been found to induce the expression of the zinc
ﬁnger transcription factors Gli1 and Gli2 in various human
cell types [34], was found to be upregulated in DiI?/SCCs.
TGFb receptors are known to be expressed by epithelial
cells undergoing EMT [34], and TGFb alone is known to
induce EMT in vitro [12]. Moreover, EGFR transcripts
were found down regulated in DiI?/SCCs demonstrating
differential activity of core stem cell pathways between
Fig. 5 Gene Expression
Analysis a Change in gene
expression, obtained from RT-
PCR analysis, in DiI?/SCC as
compared to DiI-/FCC
populations. b RT-PCR
proﬁling displaying return of
gene expression levels to that of
the original population after 30
(Panc03.27) or 60 (BxPC-3)
days of repopulating growth by
DiI?/SCC
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123DiI?/SCCs and DiI-/FCCs. EGFR receptor down-regu-
lation was further conﬁrmed through immunohistochem-
istry (data not shown).
Finally we tested whether colonies that were derived
from DiI?/SCCs were similar to pre-selection colonies.
We previously observed that DiI?/SCCs, either after 5-FU
chemotherapy or after FACS sorting, were able to re-
establish colonies of morphological diverse tumor tissue,
which were indistinguishable from the pre-selection
material after 30 (Panc03.27) or 60 (BxPC-3) days of
growth. As shown in Fig. 5b, RT-PCR analysis indicates
that the re-established colony of pancreas adenocarcinoma
cells is nearly identical to the pre-selection parental
population.
Taken together, these results from the real time PCR
analysis conﬁrmed the stem cell character of the DiI?/SCC
population and its increased invasive potential through
undergoing EMT.
Discussion
In this report we identiﬁed and characterized an intrinsic
system of slow and fast cycling cells in pancreas adeno-
carcinoma cell lines. Notably, the variations in cycling
speed were associated with a whole panel of tumor relevant
alterations. These include the increased presence of CD24/
CD44 and CD133 surface markers and ALDH expression
in DiI?/SCCs, the morphological and genetic ﬁnger print
of EMT including increased invasiveness and tumor initi-
ating potential, a shift in the activity of stem cell pathways,
and a shift in sensitivity to chemotherapy. While several of
these features have been reported to be present in both
primary and established pancreas adenocarcinoma cell
lines, as well as in other solid tumors, this report shows all
these characteristics to coincide in an easily identiﬁable
and traceable subpopulation of cells. The characteristics of
DiI?/SCCs would qualify them to be deﬁned as tumor
stem cells. However, such a term may be misleading as it
implies that tumor stem cells are founder cells with a
broader self renewal and lineage potential compared to the
bulk population of tumor cells. While we conﬁrm the
increased potential of DiI?/SCCs with regard to central
parameters including tumor initiation, chemotherapy
resistance and invasiveness, we also observed that not only
can DiI?/SCCs give rise to DiI-/FCCs, but vice versa, the
population of DiI-/FCCs can segregate DiI?/SCCs. Thus,
in contrast to the classical tumor stem cell concept that
ascribes CSCs as lying at the apex of a hierarchy [35] the
here described cells support a model of a bidirectional
potential in both subpopulation and bulk cells. If generally
applicable, this would expand the current unidirectional
concept of CSC to a more ﬂexible scheme with context
dependent state transitions. Such a scheme would accom-
modate both MET and EMT, which is observed in vivo
during metastasis. However, it may well be that both
models are valid, depending on cancer type and progres-
sion. Although we report heterogeneity in cell cycle speed
in pancreas adenocarcinoma lines, it is likely that the
phenomenon is of more general validity. Likewise, while
we report an increased tumorigenic potential in the DiI?/
SCC population, we also note that the DiI?/SCC can
transition to DiI-/FCC and vice versa. Therefore, hypo-
thetically, DiI-/FCC may be capable of generating tumors
similar to the DiI?/SCC population after a long lag
phase. While we did not observe this, one can not dis-
miss the possibility of this occurrence after a long term
investigation.
Recent reports describe a CD24
?/CD44
? population of
cells in both primary pancreas adenocarcinoma cell lines,
and in the established cell line Panc1 [4]. These cells have
also shown to be of higher tumor initiating potential, and
are positive for the stem cell pathway Hh [3]. Independent
research has also established that pancreas adenocarcinoma
can undergo EMT, and that this process may be regulated
positively by Hh and/or TGFb signaling. Finally, chemo-
therapy resistance has been associated with CD24
?/CD44
?
cells in pancreas adenocarcinoma. Similarly, as chemo-
therapy resistance and metastasis are general issues in solid
tumors, heterogeneity in key features of cell cycle control
and EMT have been reported in a multitude of tumor
models [12, 13, 31, 36–38].
There is further evidence for heterogeneity within highly
tumorigenic subpopulations in solid tumors. Previous
reports have found variability in cell surface phenotypes
used to classify CSC. Speciﬁcally in pancreatic cancer,
although overlap was found between CD133
? and CD24
?/
CD44
? cells, it was highly variable and only 10–40% of
CD24
?/CD44
? cells were found to also express CD133
[5]. In other reports, high aldehyde dehydrogenase 1
(ALDH1A1) activity was shown to identify the tumori-
genic fraction [6, 7]. This ALDH1A1? population though,
was found to have a surprisingly small overlap with the
previously described breast CSC (CD44
?/CD24
-/low)
phenotype [26]. In this study, an overlap of SCC and
CD24
?/CD44
?, CD133
? and ALDH was found; the nature
of the CD24
-/CD44
?, CD133
- and ALDH
- SCC popu-
lation is yet still to be determined.
Using DiI to identify slow cycling cancer stem-like cell
populations is a simple procedure that yields an easily
identiﬁable, traceable and isolatable population. Yet, as
with any label retention technique, it has some weaknesses.
The downside to using this method is simply that one must
wait for the bulk of the population to cycle the dye out
before identiﬁcation of the label retaining cells can occur.
This can mean weeks of cell growth and expansion while
Clin Exp Metastasis (2009) 26:611–623 621
123keeping large numbers of cells in culture in order to obtain
a sufﬁcient number of DiI?/SCC after sorting the popu-
lations. Moreover, although label retention could be used to
identify SCC in primary cell cultures, one ﬁnal drawback is
that it would require these cells to be passaged a number of
times; potentially altering the characteristics of the original
primary tissue. However, when comparing this technique
of cancer stem-like cell puriﬁcation to classical ones (such
as direct antibody targeting on primary tissue) this method
yields the possibility of obtaining much more material,
thereby allowing many more functional assays to be carried
out. In conclusion, the DiI label retention technique
employed to isolate slowly cycling cancer cells could aid
the understanding of tumor heterogeneity and the devel-
opment of therapeutic tools. This study represents a novel
step in better deﬁning the biological activities of tumori-
genic subpopulations within the vast heterogeneous tumor
microenvironment.
Of note, during the review process of our manuscript,
the connection between SCC and CSC has also been
explored and strongly supported by the Bieberich labora-
tory [39], in which SCC in the breast cancer cell line 4T1
were found to have CSC-like properties in vitro and in
vivo. These data further support our ﬁndings and suggest
that they are not limited to pancreatic adenocarcinoma
cells.
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